Clinical Trials Logo

Clinical Trial Summary

Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017, conferring 0.24% of total disability-adjusted life-years globally. Due to the absence of knowledge of AF pathogenesis, currently, available therapies do not prevent AF onset or progression in 85% of patients. Despite the identification of novel druggable targets that are involved in the pathogenesis of AF, the translation of these findings to clinical drug studies is limited. Postoperative atrial fibrillation (POAF) is the most common type of secondary AF. The incidence of POAF after coronary artery bypass grafting (CABG) is approximately 30%. About 16% of patients developed POAF in cardiac surgery even with the international guideline recommended perioperative beta-blocker intervention. Remimazolam is a newly approved benzodiazepine sedative indicated for the induction and maintenance of procedural sedation in adults, with significantly reduced sedation and recovery time. It was also found to be with an anti-inflammatory effect and therefore might have an impact on POAF since AF is closely related to the inflammatory response of myocardial tissue and inflammatory factors such as TNF-α. So, the RePAF trial intends to explore whether remimazolam application in induction and maintenance for general anesthesia during cardiac surgery can reduce the incidence of POAF in patients with CABG, and the effect on the postoperative plasma levels of inflammatory factors and stress factors.


Clinical Trial Description

Postoperative atrial fibrillation (POAF) presented a 30% incidence in cardiac surgery and 16% even under beta-blocker treatment, leading to serious complications. Inflammation is a key mechanism that promotes POAF. Remimazolam is a newly approved benzodiazepine sedative with anti-inflammatory effects. However, the impact of remimazolam on POAF remains unknown. To explore whether or not remimazolam can reduce the POAF in coronary artery bypass grafting (CABG) patients, a first open-phase trial in which 50 patients (randomized 1:1 to Remimazolam and control groups) will be enrolled as a pilot study to obtain parameters for sample size calculation. A double-blind randomized controlled trial will be then conducted to explore remimazolam's effect on POAF and inflammatory factors' blood levels in patients that receive selective CABG. The blood level of inflammatory factors, stress factors (epinephrine, norepinephrine, cortisol, adrenocorticotropic hormone, corticotropin-releasing hormone), myocardial injury markers, and hemodynamic parameters will also be assessed. This 2-phase clinical trial will provide novel evidence for the newly approved sedative drug, remimazolam, and with detailed data for inflammatory and myocardial injury endpoints. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05891145
Study type Interventional
Source Yangzhou University
Contact Xiaojun He, MD, Ph.D.
Phone +86-13524954567
Email xhe34baltimore@163.com
Status Recruiting
Phase N/A
Start date February 1, 2023
Completion date December 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT01850082 - Randomized Endo-Vein Graft Prospective N/A
Not yet recruiting NCT04657835 - Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery. N/A
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01528514 - Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study N/A
Completed NCT01378221 - VItamin D Metabolism in SEnescent Cardiac Surgery Patients N/A
Completed NCT00848796 - Comparative Study of Two Brands of Heparin Already on the Market N/A
Not yet recruiting NCT05552586 - Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery N/A
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Completed NCT00420667 - Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery N/A
Recruiting NCT04197700 - The PRESSURE CABG Cardiac Surgery Trial N/A
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Not yet recruiting NCT06326996 - Thiamine Intervention and Coronary Artery Bypass Grafting N/A
Not yet recruiting NCT02732574 - Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery N/A
Completed NCT01182688 - Prospective Review of Procalcitonin After Cardiac Surgery N/A
Completed NCT00903604 - Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2
Completed NCT02737215 - Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Recruiting NCT05441358 - Assessment of Platelet Function in Patients Undergoing Open Heart Surgery
Recruiting NCT02400125 - China Cardiovascular Surgery Registry N/A